Evaluation of Screening for Visual Disorders of the Old Subject in Consultation Memory
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Number of participants with presence of an ophthalmological disease (symptomatic or not) after clinical evaluation.
研究概览
简要总结
Visual disorders are often overlooked in the treatment of cognitive disorders of the elderly. Yet the visual deficit impacts the quality of life, the evolution of the autonomy and psycho-behavioral disorders in cognitive diseases. The main objective of the study is to evaluate the prevalence of visual disorders among elderly patients at consultant outpatient center of Nantes clinical gerontology as part of the consultation geriatric memory. Secondary objectives are to describe ophthalmological diseases detected and taken into the proposed ophthalmic load, to determine if there are associations between eye diseases and cognitive disorders, to estimate the proportion of patients who may have an ophthalmologic evaluation to determine the cognitive profiles and geriatric evaluation and ocular pathological, depending on the assessment of arterial stiffness. The results of this study will build a testing strategy to promote access of older patients with cognitive impairment to vision care.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 65 Years 至 —(Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Elderly over 65 years,
- •Subject to consultation from memory Clinical Gerontology ambulatory center Nantes University Hospital
- •Current use of spoken French
- •Patient (or legal guardian, if applicable) has given its written consent
- •Patient affiliated to a social security scheme
排除标准
- •Life expectancy lower 1 year
- •Mobility limitation preventing the installation retinal
- •Major disorders and productive behavior does not allow participation in diagnostic procedures.
- •Inability to respond to instructions when performing ophthalmological examinations.
结局指标
主要结局
Number of participants with presence of an ophthalmological disease (symptomatic or not) after clinical evaluation.
时间窗: 6 month
次要结局
未报告次要终点
